Clinical trial · Interventional
Vinorelbine for Recurrent ALCL-2017
Phase II Study of Vinorelbine for Children with Recurrent Anaplastic Large Cell Lymphoma
NCT03443128CI-TRIAL-00085953completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to assess the efficiency and safety of vinorelbine in the treatment of relapsed / advanced ALCL in children and adolescents.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Anaplastic Large Cell Lymphoma | Anaplastic Large Cell Lymphoma | ONTOLOGY_EXACT | 0.90 |
| Vinorelbine | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Vinorelbine | Drug | Vinorelbine | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Vinorelbine monotherapy treatment
- description
- Patients will be treated with Vinorelbine. Four weeks as a course. There are 20 courses in total.
- interventionNames
- Drug: Vinorelbine
Primary outcomes (2)
- measure
- Progression Rate
- timeFrame
- 4 weeks
- description
- The progression rate will be obtained from the results of simple assessment after one course.
- measure
- CR/CRu Rate
- timeFrame
- 8 weeks
- description
- The CR/CRu rate will be obtained from the results of simple assessment, CT and FDG-PET after two courses.
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: Children and adolescents with a clear diagnosis of recurrent / progressive ALCL at Shanghai Children's Medical Center or other centers since September 2017 include: Diagnosed as ALCL, already received first-line treatment, but get disease progression; After receiving ALCL treatment has got CR then diagnosed relapse, need for pathological diagnosis. Exclusion Criteria: Patients with other systemic diseases, severe infections or critically illness.
References
Publications (0)
Data not yet available
No reference posted for this study.